middle.news
Neuren Launches First US Site for Phelan-McDermid Phase 3 Trial
10:38pm on Friday 29th of August, 2025 AEST
•
Healthcare
Read Story
Neuren Launches First US Site for Phelan-McDermid Phase 3 Trial
10:38pm on Friday 29th of August, 2025 AEST
Key Points
First US site initiated for NNZ-2591 Phase 3 trial in Phelan-McDermid syndrome
Trial to enroll approximately 160 children aged 3-12 with no approved treatments
Randomized, double-blind, placebo-controlled design with 13-week treatment period
Open-label extension for 12 months available for all participants
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Neuren Pharmaceuticals (ASX:NEU)
OPEN ARTICLE